ICI Pharma's Nolvadex (tamoxifen)
Executive Summary
ICI Pharma's Nolvadex (tamoxifen): Anti-estrogen drug receives supplemental approval for use in treating breast cancer in premenopausal women, as alternative to mastectomy. The oral hormone product is already indicated as a treatment for postmenopausal breast cancer and for use either alone or in combination with other anticancer agents following surgery in postmenopausal node-positive patients. The company estimates the U.S. patient population for the new indication at 14,000: 5,000 women who have advanced disease at diagnosis and 9,000 women with recurring disease.